Letong Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Letong Cai has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jiaxiong Tan
Tianjin Medical University Cancer Institute and Hospital
2 shared publications - Ling Xu
Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China
2 shared publications - Yangqiu Li
Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, PR China
2 shared publications - Yuchen Li
Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China
2 shared publications A.H. Jan Danser
Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam University, Rotterdam, Netherlands
1 shared publication- Bing Liu
Marshall Laboratory of Biomedical Engineering,Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011657
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells
Background: Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear. Methods: Orthotopic models of pancreatic cancer and melanoma in Pcsk9 -deficient mice were established and tumor-infiltrating immune cells were analyzed using single-cell RNA sequencing and flow cytometry. The effect of genetic disruptions of PCSK9 on murine CD8 + T cells and human chimeric antigen receptor (CAR)-T cells was evaluated both in vitro and in vivo. Results: Ablation of host Pcsk9 remarkably suppressed tumor growth and prolonged the survival of tumor-bearing mice, while tumor cells still express PCSK9. The enhanced tumor suppression in Pcsk9 -deficient mice depended on CD8 + T cells. Notably, PCSK9 expression was induced in CD8 + tumor-infiltrating lymphocytes (TILs). Consequently, Pcsk9 ablation potentiated the antitumor capacity of CD8 + T cells, showing increased intratumoral infiltration and improved cytotoxic function, along with higher proportions of both effector-memory precursor exhausted (T PEX ) and terminally exhausted (T TEX ) CD8 + TILs. Additionally, disruption of PCSK9 in both murine CD8 + T cells and human CAR-T cells, synergistic with PD-1 blockade, promoted tumor suppression. Conclusion: These findings indicate that PCSK9 inhibits the antitumor function of CD8 + T cells, suggesting it may be a promising target for enhancing T-cell-based cancer immunotherapy.
- 15 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011657
Open AccessDisruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells
Background: Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear. Methods: Orthotopic models of pancreatic cancer and melanoma in Pcsk9 -deficient mice were established and tumor-infiltrating immune cells were analyzed using single-cell RNA sequencing and flow cytometry. The effect of genetic disruptions of PCSK9 on murine CD8 + T cells and human chimeric antigen receptor (CAR)-T cells was evaluated both in vitro and in vivo. Results: Ablation of host Pcsk9 remarkably suppressed tumor growth and prolonged the survival of tumor-bearing mice, while tumor cells still express PCSK9. The enhanced tumor suppression in Pcsk9 -deficient mice depended on CD8 + T cells. Notably, PCSK9 expression was induced in CD8 + tumor-infiltrating lymphocytes (TILs). Consequently, Pcsk9 ablation potentiated the antitumor capacity of CD8 + T cells, showing increased intratumoral infiltration and improved cytotoxic function, along with higher proportions of both effector-memory precursor exhausted (T PEX ) and terminally exhausted (T TEX ) CD8 + TILs. Additionally, disruption of PCSK9 in both murine CD8 + T cells and human CAR-T cells, synergistic with PD-1 blockade, promoted tumor suppression. Conclusion: These findings indicate that PCSK9 inhibits the antitumor function of CD8 + T cells, suggesting it may be a promising target for enhancing T-cell-based cancer immunotherapy.
- Open Access
- 29 September 2023
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 16 (1) , 1
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
- 29 September 2023
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 16 (1) , 1
Open AccessCorrection: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
- Top Cited PapersOpen Access
- 5 September 2023
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 16 (1) , 1-34
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened and their effectiveness evaluated in preclinical and clinical trials. Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) constitute the second wave of immunotherapy targets that show great promise for use in the treatment of solid tumors and leukemia. To promote the research and clinical application of ICBs directed at these targets, we summarize their discovery, immunotherapy mechanism, preclinical efficiency, and clinical trial results in this review.
- 5 September 2023
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 16 (1) , 1-34
Top Cited PapersOpen AccessTargeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened and their effectiveness evaluated in preclinical and clinical trials. Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) constitute the second wave of immunotherapy targets that show great promise for use in the treatment of solid tumors and leukemia. To promote the research and clinical application of ICBs directed at these targets, we summarize their discovery, immunotherapy mechanism, preclinical efficiency, and clinical trial results in this review.